Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial

In this phase 2 trial, 142 patients with resectable or borderline resectable NSCLC received neoadjuvant durvalumab plus chemotherapy, with subsequent surgery or chemoradiotherapy guided by multidisciplinary assessment. The overall resection rate was 74.6%, and 131 of 142 patients (92.3%) went on to surgery or chemoradiotherapy. ctDNA clearance between baseline and before surgery or chemoradiotherapy is listed as a secondary endpoint; the abstract does not report those results.

Nature MedicinePubMed 42934326DOI 10.1038/s41591-026-04742-7